Glenmede Trust Co. NA Has $10.12 Million Stake in ICU Medical, Inc. $ICUI

Glenmede Trust Co. NA reduced its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 11.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,366 shares of the medical instruments supplier’s stock after selling 9,928 shares during the quarter. Glenmede Trust Co. NA’s holdings in ICU Medical were worth $10,121,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ICUI. AQR Capital Management LLC increased its holdings in ICU Medical by 2.5% during the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock worth $1,297,000 after purchasing an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ICU Medical by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock valued at $1,772,000 after purchasing an additional 560 shares in the last quarter. United Services Automobile Association acquired a new position in shares of ICU Medical during the first quarter worth about $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of ICU Medical by 32.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after buying an additional 16,680 shares during the period. Finally, Intech Investment Management LLC boosted its position in shares of ICU Medical by 38.6% during the first quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after buying an additional 3,326 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ICUI shares. Piper Sandler dropped their target price on ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Sanford C. Bernstein downgraded ICU Medical to a “market perform” rating in a research report on Monday, June 15th. KeyCorp raised their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Finally, BTIG Research started coverage on shares of ICU Medical in a research report on Monday, June 15th. They issued a “buy” rating and a $170.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $172.00.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $172.94 on Tuesday. The stock has a market capitalization of $4.32 billion, a price-to-earnings ratio of 93.48, a PEG ratio of 2.35 and a beta of 0.76. The business has a 50-day moving average of $148.81 and a 200-day moving average of $140.40. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17. ICU Medical, Inc. has a fifty-two week low of $107.00 and a fifty-two week high of $176.27.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same quarter in the prior year, the company posted $1.72 earnings per share. ICU Medical’s revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president owned 19,460 shares of the company’s stock, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the sale, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is owned by insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.